News Chart Akeso, Inc.

Equities

Delayed Hong Kong S.E. Other stock markets 09:29:05 16/01/2026 am IST			5-day change	1st Jan Change
118.80 ^HKD	-2.54%		-6.90%	+5.13%

12/12	Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab	CI
11/12	Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025	CI

7d87c9704f7.qsjbkVBk9Mzu0kSItMk6O4EuM_K2iHrudQKhixZwtR8.0-W39jVTh4qithv8-J5pSuJBfZXYwjK8GF2T3H0q-nuZh5bSAFSBhrefdA~2a5e790920420cc718edb33ca928a62a